Insulet (PODD) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25.93%. A quarter ago, it was expected that this maker of insulin infusion systems would post earnings of $1.05 per share when it actually produced earnings of $1.15, delivering a surprise of 9.52%.Over the last four quart ...

InfuSystems Holdings, Inc. (INFU) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 66.67%. A quarter ago, it was expected that this company would post earnings of $0.08 per share when it actually produced earnings of $0.04, delivering a surprise of -50%.Over the last four quarters, the company ...

Core Insights - Evolus, Inc. reported a quarterly loss of $0.18 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.10, marking an earnings surprise of -80% [1] - The company's revenues for the quarter ended March 2025 were $68.52 million, missing the Zacks Consensus Estimate by 4.83%, but showing an increase from $59.33 million year-over-year [2] - Evolus has not surpassed consensus EPS estimates over the last four quarters and has only topped revenue estimates once in that same period [2] Company Performance - Evolus shares have increased by approximately 5.2% since the beginning of the year, contrasting with a -4.7% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $82.86 million, and for the current fiscal year, it is -$0.01 on revenues of $351.43 million [7] Earnings Outlook - The estimate revisions trend for Evolus is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] - The outlook for the Medical - Products industry, to which Evolus belongs, is in the bottom 28% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Company Performance - Myomo, Inc. reported a quarterly loss of $0.08 per share, which aligns with the Zacks Consensus Estimate, an improvement from a loss of $0.10 per share a year ago [1] - The company posted revenues of $9.83 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 6.29%, compared to revenues of $3.75 million in the same quarter last year [2] - Over the last four quarters, Myomo has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2][3] Stock Outlook - Myomo shares have declined approximately 25.9% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $10.35 million, and for the current fiscal year, it is -$0.07 on revenues of $50.95 million [7] Industry Context - The Medical - Products industry, to which Myomo belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Myomo's stock performance [5][6]

Company Performance - Biote Corp. reported quarterly earnings of $0.08 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, but down from $0.23 per share a year ago, representing an earnings surprise of 33.33% [1] - The company posted revenues of $48.99 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.51%, compared to $46.8 million in the same quarter last year [2] - Biote Corp. has surpassed consensus EPS estimates in all four of the last quarters, but has only topped consensus revenue estimates once during the same period [2] Stock Performance - Biote Corp. shares have declined approximately 45.5% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] - The current Zacks Rank for Biote Corp. is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.08 on revenues of $50.2 million, and for the current fiscal year, it is $0.39 on revenues of $205.41 million [7] - The outlook for the Medical - Products industry, to which Biote Corp. belongs, is currently in the bottom 28% of over 250 Zacks industries, which may impact the stock's performance [8]

Group 1: Earnings Performance - AdaptHealth Corp. reported quarterly earnings of $0.01 per share, matching the Zacks Consensus Estimate, compared to $0.02 per share a year ago [1] - The company posted revenues of $777.88 million for the quarter, exceeding the Zacks Consensus Estimate by 1.72%, but down from $792.5 million year-over-year [2] - Over the last four quarters, AdaptHealth has surpassed consensus EPS estimates three times [1][2] Group 2: Stock Performance and Outlook - AdaptHealth shares have declined approximately 8.6% since the beginning of the year, while the S&P 500 has decreased by 3.9% [3] - The company's earnings outlook will be crucial for future stock movements, with current consensus EPS estimates at $0.28 for the coming quarter and $1.12 for the current fiscal year [4][7] - The current Zacks Rank for AdaptHealth is 3 (Hold), indicating expected performance in line with the market in the near future [6] Group 3: Industry Context - The Medical - Products industry, to which AdaptHealth belongs, is currently ranked in the bottom 26% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that investors should monitor these revisions closely [5]

Group 1 - Cerus reported a quarterly loss of $0.04 per share, better than the Zacks Consensus Estimate of a loss of $0.05, representing an earnings surprise of 20% [1] - The company posted revenues of $43.24 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 2.95%, and up from $38.37 million a year ago [2] - Cerus has surpassed consensus EPS estimates three times over the last four quarters [2] Group 2 - The stock has underperformed, losing about 14.3% since the beginning of the year, compared to the S&P 500's decline of 5.3% [3] - The current consensus EPS estimate for the coming quarter is -$0.02 on revenues of $49.5 million, and -$0.10 on revenues of $198 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Products is in the bottom 28% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Company Performance - SurModics reported a quarterly loss of $0.13 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.06, and a decline from earnings of $0.07 per share a year ago, resulting in an earnings surprise of -116.67% [1] - The company posted revenues of $28.09 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 8.73%, and down from $31.96 million in the same quarter last year [2] - SurModics has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates two times in the same period [2] Stock Performance - SurModics shares have declined approximately 21.9% since the beginning of the year, compared to a decline of 5.5% for the S&P 500 [3] - The current Zacks Rank for SurModics is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.01 on revenues of $30.47 million, and for the current fiscal year, it is -$0.01 on revenues of $124.01 million [7] - The estimate revisions trend for SurModics is mixed, and changes in earnings expectations may occur following the recent earnings report [6] Industry Context - The Medical - Products industry, to which SurModics belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact SurModics' stock performance [5]

分组1 - ResMed reported quarterly earnings of $2.37 per share, exceeding the Zacks Consensus Estimate of $2.36 per share, and up from $2.13 per share a year ago, representing an earnings surprise of 0.42% [1] - The company achieved revenues of $1.29 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.53%, compared to $1.2 billion in the same quarter last year [2] - ResMed has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] 分组2 - The stock has declined approximately 6.4% since the beginning of the year, while the S&P 500 has decreased by 10.1% [3] - The current consensus EPS estimate for the upcoming quarter is $2.45 on revenues of $1.32 billion, and for the current fiscal year, it is $9.47 on revenues of $5.11 billion [7] - The Zacks Industry Rank for Medical - Products is in the bottom 26% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Company Overview - FitLife Brands Inc. (FTLF) shares increased by 13.1% to close at $13.34, following a period of 12.7% loss over the past four weeks, indicating a significant rebound in investor sentiment [1] - The stock's price surge was supported by high trading volume, with more shares exchanged than usual [1] Insider Activity - Investor optimism was bolstered by director Todd Ordal purchasing 300 shares at $12.07 per share on April 15, and another director, Matthew Lingenbrink, acquiring 3,000 shares for approximately $36,510 [2] Earnings Expectations - FitLife Brands is projected to report quarterly earnings of $0.24 per share, reflecting a year-over-year increase of 9.1%, while revenues are expected to be $15.84 million, a decrease of 4.3% from the previous year [3] - The consensus EPS estimate has been revised 100% lower over the last 30 days, which typically does not correlate with price appreciation [4] Industry Context - FitLife Brands operates within the Zacks Medical - Products industry, where another company, LeMaitre Vascular (LMAT), reported a 1.9% increase in stock price, closing at $86.28, with a slight decline of 0.2% over the past month [4] - LeMaitre's consensus EPS estimate remains unchanged at $0.50, representing a year-over-year increase of 13.6%, and it holds a Zacks Rank of 2 (Buy) [5]